JP Morgan Chase
LPCN icon

JP Morgan Chase’s Lipocine LPCN Stock Holding History

JP Morgan Chase’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97K Buy
+392
New +$3.42K ﹤0.01% 6957
2025
Q2 		– Sell
-11
Closed -$35 – 7409
2025
Q1 		$35 Sell
11
-1
-8% -$4 ﹤0.01% 7035
2024
Q4 		$59 Hold
12
– – ﹤0.01% 7099
2024
Q3 		$54 Buy
+12
New +$60 ﹤0.01% 7112
2024
Q2 		– Sell
-12
Closed -$62 – 7586
2024
Q1 		$62 Buy
12
+3
+33% +$12 ﹤0.01% 6988
2023
Q4 		$25 Sell
9
-174
-95% -$460 ﹤0.01% 7310
2023
Q3 		$538 Buy
183
+6
+3% +$25 ﹤0.01% 6715
2023
Q2 		$885 Buy
177
+1
+0.6% +$5 ﹤0.01% 6473
2023
Q1 		$1K Hold
176
– – ﹤0.01% 6529
2022
Q4 		$1K Hold
176
– – ﹤0.01% 6420
2022
Q3 		$1K Hold
176
– – ﹤0.01% 6342
2022
Q2 		$2K Hold
176
– – ﹤0.01% 6288
2022
Q1 		$4K Hold
176
– – ﹤0.01% 6351
2021
Q4 		$3K Hold
176
– – ﹤0.01% 6467
2021
Q3 		$3K Hold
176
– – ﹤0.01% 6293
2021
Q2 		$4K Hold
176
– – ﹤0.01% 6153
2021
Q1 		$5K Hold
176
– – ﹤0.01% 5865
2020
Q4 		$4K Sell
176
-777
-82% -$18.7K ﹤0.01% 5471
2020
Q3 		$22K Buy
953
+777
+441% +$20.6K ﹤0.01% 5124
2020
Q2 		$4K Hold
176
– – ﹤0.01% 5204
2020
Q1 		$1K Hold
176
– – ﹤0.01% 5209
2019
Q4 		$1K Hold
176
– – ﹤0.01% 5559
2019
Q3 		$8K Hold
176
– – ﹤0.01% 5528
2019
Q2 		$6K Sell
176
-777
-82% -$24K ﹤0.01% 5617
2019
Q1 		$37K Buy
+953
New +$29.2K ﹤0.01% 5233
2018
Q4 		– Sell
-5,613
Closed -$132K – 5814
2018
Q3 		$132K Buy
5,613
+3,329
+146% +$81.9K ﹤0.01% 4848
2018
Q2 		$50K Buy
+2,284
New +$54.4K ﹤0.01% 5079
2018
Q1 		– Sell
-533
Closed -$31K – 5519
2017
Q4 		$31K Sell
533
-797
-60% -$49.6K ﹤0.01% 5052
2017
Q3 		$90K Buy
+1,330
New +$96.2K ﹤0.01% 4331
2017
Q2 		– Sell
-11,393
Closed -$755K – 5095
2017
Q1 		$755K Sell
11,393
-689
-6% -$44.7K ﹤0.01% 3531
2016
Q4 		$756K Sell
12,082
-247
-2% -$15.6K ﹤0.01% 3567
2016
Q3 		$935K Buy
+12,329
New +$764K ﹤0.01% 3164
2016
Q2 		– Sell
-1,308
Closed -$226K – 4879
2016
Q1 		$226K Buy
+1,308
New +$223K ﹤0.01% 3574
2015
Q3 		– Sell
-2,065
Closed -$301K – 4002
2015
Q2 		$301K Buy
+2,065
New +$256K ﹤0.01% 3717

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

JP Morgan Chase's LPCN Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Lipocine (LPCN) in Q1 2026: 392 shares worth $2.97K. The stake represents ﹤0.01% of the portfolio and ranks #6957 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in LPCN as recently as Q1 2025.

JP Morgan Chase first reported a position in LPCN in Q2 2015 and has held it in 34 quarters since. The position peaked at $935K in Q3 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • JP Morgan Chase held 392 shares of Lipocine worth $2.97K as of Q1 2026.
  • Lipocine was a new JP Morgan Chase position in Q1 2026.
  • Lipocine made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6957 holding.
  • JP Morgan Chase first reported a position in Lipocine in Q2 2015 and has held it in 34 quarters since.
  • JP Morgan Chase's Lipocine position peaked at $935K in Q3 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.